Preparation and In Vitro Evaluation of 131I-BmK CT as a Glioma-Targeted Agent

被引:10
|
作者
Zhao, Jinhua [1 ]
Qiao, Wenli [1 ]
Zhang, Yuna [1 ]
Shao, Xiaoxia [2 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Nucl Med, Peoples Hosp 1, Shanghai 200080, Peoples R China
[2] Tongji Univ, Inst Prot Res, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
I-131; glioma; radionuclide therapy; scorpion toxin; targeted therapy; PHASE-I; MALIGNANT GLIOMAS; BRAIN-TUMORS; CHLOROTOXIN; SCORPION; PEPTIDE;
D O I
10.1089/cbr.2009.0704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Buthus martensi Karsch (BmK) CT, a kind of scorpion toxin peptide, was found to inhibit glioma cell proliferation in previous researches. I-131-BmK CT may have more inhibition effect and could be used as a glioma cell-targeted therapy and imaging agent. The purpose of this study was to investigate whether I-131-BmK CT could specifically conjugate with C6 glioma cell and induce glioma cell inhibition in vitro. Methods: After cloning, expression, and purification, BmK CT was labeled with I-131 by indirect labeling (Bolton-Hunter method). The cell conjugation experiment was performed to investigate the connection between the reciprocal of cell conjugation rate and the reciprocal of cell count. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method and flow cytometry were used to detect the inhibition effect of BmK CT and I-131-BmK CT on glioma cell proliferation. Results: I-131-BmK CT was successfully prepared with the overall yield of 34.5%. The cell conjugation experiment indicated that I-131-BmK CT could specifically conjugate with C6 cells. MTT tests indicated that both BmK CT and I-131-BmK CT could inhibit C6 growth. The ability of I-131-BmK CT to inhibit cell growth is superior to that of BmK CT. The inhibitory rate (IR) of glioma cells was 60.5% (p < 0.01) at the concentration of 2 mu g/mL with BmK CT. And the IR was 71.2% (p < 0.01) at the radioactivity concentration of 50 mu Ci/mL (concentration was much lower than 2 mu g/mL) with I-131-BmK CT. BmK CT could block the C6 glioma cell cycle in the G0/G1 stage. I-131-BmK CT blocked the cell cycle in the S stage (the proportions of C6 in the S, G0/G1, and G2/M phases were 24.5% +/- 0.4% vs. 44.0% +/- 2.3%, 63.9% +/- 0.6% vs. 51.8% +/- 1.6%, and 11.6% +/- 1.0% vs. 4.3 +/- 0.7% [p < 0.05], respectively, at an initial radioactivity concentration of 50 mu Ci/mL). Conclusions: On the basis of cytology experiments, it was found that I-131-BmK CT could specifically conjugate with C6 glioma cell and inhibit cell growth. Hence, it may be used as a glioma-targeted agent.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 50 条
  • [31] Excretion and toxicity evaluation of 131I-Sennoside A as a necrosis-avid agent
    Yin, Zhiqi
    Sun, Lidan
    Jin, Qiaomei
    Song, Shaoli
    Feng, Yuanbo
    Liao, Hong
    Ni, Yicheng
    Zhang, Jian
    Liu, Wei
    XENOBIOTICA, 2017, 47 (11) : 980 - 988
  • [32] Legumain-mediated self-assembly of a 131I-labelled agent for targeted radiotherapy of tumors
    Wang, Qiqi
    Lu, Chunmei
    Li, Ke
    Xia, Yongmei
    Qiu, Ling
    Lin, Jianguo
    JOURNAL OF MATERIALS CHEMISTRY B, 2022, 10 (13) : 2251 - 2259
  • [33] Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution
    Adli A. Selim
    M. A. Motaleb
    Hend A. Fayez
    Pharmaceutical Chemistry Journal, 2022, 55 : 1163 - 1168
  • [34] Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines
    Ronald J. Bernardi
    Amanda R. Lowery
    Patrick A. Thompson
    Susan M. Blaney
    Jennifer L. West
    Journal of Neuro-Oncology, 2008, 86 : 165 - 172
  • [35] Lung Cancer-Targeted [131I]-Iodoshikonin as Theranostic Agent: Radiolabeling, In Vivo Pharmacokinetics and Biodistribution
    Selim, Adli A.
    Motaleb, M. A.
    Fayez, Hend A.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2022, 55 (11) : 1163 - 1168
  • [36] Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines
    Bernardi, Ronald J.
    Lowery, Amanda R.
    Thompson, Patrick A.
    Blaney, Susan M.
    West, Jennifer L.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 165 - 172
  • [37] THE NORMAL AND ABNORMAL DISTRIBUTION OF THE ADRENOMEDULLARY IMAGING AGENT M-[I-131]IODOBENZYLGUANIDINE (I-131 MIBG) IN MAN - EVALUATION BY SCINTIGRAPHY
    NAKAJO, M
    SHAPIRO, B
    COPP, J
    KALFF, V
    GROSS, MD
    SISSON, JC
    BEIERWALTES, WH
    JOURNAL OF NUCLEAR MEDICINE, 1983, 24 (08) : 672 - 682
  • [38] Preparation of an imaging agent for cerebral muscarinic acetylcholine receptor, (R,S)(131)I-QNB
    DING Shi-Yu
    Department of Nuclear Medicine
    Nuclear Science and Techniques, 2003, (01) : 64 - 68
  • [39] BmK CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells in vitro through blocking the AKT signaling pathway
    Du, Jun
    Wang, Ruijie
    Yin, Litian
    Fu, Yuejun
    Cai, Yuqing
    Zhang, Zhiyun
    Liang, Aihua
    ONCOLOGY LETTERS, 2018, 15 (02) : 1537 - 1544
  • [40] Preclinical evaluation of 131I-Bevacizumab - A prospective agent for radioimmunotherapy in VEGF expressing cancers
    Kameswaran, Mythili
    Sarma, Haladhar Dev
    Dash, Ashutosh
    APPLIED RADIATION AND ISOTOPES, 2017, 123 : 109 - 113